



Connecticut Health Plan

Public Dashboard

Reporting Period: January 2023 - December 2023 (Current Period) ; January 2022 – December 2022 (Prior Period)

Includes all covered plan participants (Active, Non-Medicare Retirees and Medicare Retirees) unless otherwise noted



Table of Contents

Page 3 – Enrollment (Actives)

Page 4 – Enrollment (Retirees)

Page 5 – Plan Paid By Setting

Page 9 – Plan Paid By Age Band and Gender

Page 13 – Emergency Room Visits

Page 17 – Top 15 Drugs

Page 21 – Top 15 Prescription Drug Disease Indications

Page 25 – Top 15 Diagnosis Categories for Medical Claims


Page 29 – Distribution of Claims By Membership



Enrollment: Actives

January 2023 – December 2023

Average Employee and Dependent Counts



Average Employee and Dependent Counts

Line of Business	Employee Count	Dependent Count	Total Count	PEPM ¹
Partnership	26,216	32,847	59,063	\$1,580.94 ²
State	48,534	67,221	115,755	\$1,464.65
Total	74,750	100,068	174,818	\$1,505.43

¹ Per Employee Per Month


² Partnership is higher due to membership located in counties that have a higher average cost of care, Regional pricing adjustments account for this disparity.



Enrollment: Retirees

January 2023 – December 2023

Average Retiree and Dependent Counts



Average Retiree and Dependent Counts				
Status	Retiree Count	Dependent Count	Total Count	PEPM ¹
Non-Medicare Retirees	17,819	16,811	34,630	\$1,618
Medicare Retirees	43,676	15,807	59,483	\$1,249

¹ Per Employee Per Month – these numbers include State and Partnership retirees. As Partnership retiree membership increases, they will be reported separately.





Plan Paid By Setting – State Plan Active Population

January 2023 – December 2023 (Current Period); January 2022 – December 2022 (Prior Period)

Current vs Prior

Total: **Prior – \$1.06B** **Current – \$1.07B**



Other includes ancillary claims such as Home Health, Hospice, Durable Medical Equipment (DME), Ambulance etc.





Plan Paid By Setting – State Plan Non-Medicare Retirees

January 2023 – December 2023 (Current Period); January 2022 – December 2022 (Prior Period)

Current vs Prior

Total: **Prior – \$443M** **Current – \$436M**



Other includes ancillary claims such as Home Health, Hospice, Durable Medical Equipment (DME), Ambulance etc.





Plan Paid By Setting – State Plan Medicare Retirees

January 2023 – December 2023 (Current Period); January 2022 – December 2022 (Prior Period)

Current vs Prior

Total: **Prior – \$1.01B** **Current – \$1.4B**



Other includes ancillary claims such as Home Health, Hospice, Durable Medical Equipment (DME), Ambulance etc.





Plan Paid By Setting – Partnership Plan (includes retirees)

January 2023 – December 2023 (Current Period); January 2022 – December 2022 (Prior Period)

Current vs Prior

Total: **Prior – \$651M** **Current – \$642M**




Other includes ancillary claims such as Home Health, Hospice, Durable Medical Equipment (DME), Ambulance etc.




Plan Paid By Age and Gender – State Plan Active Population January 2023 – December 2023

Plan Paid By Age Band



Plan Paid By Age Band and Gender




Age Band	0-5	6-19	20-30	31-40	41-50	51-64	65+
Percent Of Tot	6.6%	21.5%	15.1%	14.8%	16.9%	22.2%	2.9%
Pct of Enrollment – Male	52.5%	51.0%	49.6%	45.0%	45.0%	46.1%	58.4%
Pct of Enrollment - Female	47.5%	49.0%	50.4%	55.0%	55.0%	53.9%	41.6%




Plan Paid By Age and Gender – State Plan Non-Medicare January 2023 – December 2023

Plan Paid By Age Band





Plan Paid By Age Band and Gender



Age Band	0-5	6-19	20-30	31-40	41-50	51-64	65+
Percent Of Tot	0.5%	11.7%	18.9%	0.8%	6.8%	60.2%	1.2%
Pct of Enrollment – Male	42.2%	50.3%	49.9%	35.6%	39.8%	43.9%	50.3%
Pct of Enrollment - Female	57.8%	49.7%	50.1%	64.4%	60.2%	56.1%	49.7%



Plan Paid By Age and Gender – State Plan Medicare Retirees January 2023 – December 2023




Age Band	20-30	31-40	41-50	51-64	65+
Percent Of Tot	0.1%	0.2%	0.2%	2.7%	96.9%
Pct of Enrollment – Male	62.9%	53.4%	52.5%	41.9%	43.5%
Pct of Enrollment - Female	37.1%	46.6%	47.5%	58.1%	56.5%



Plan Paid By Age and Gender – Partnership Plan (incl. retirees)


January 2023 – December 2023

Plan Paid By Age Band



Plan Paid By Age Band and Gender

Female Male



Age Band	0-5	6-19	20-30	31-40	41-50	51-64	65+
Percent Of Tot	5.9%	18.0%	15.8%	13.1%	13.9%	22.7%	10.6%
Pct of Enrollment – Male	50.4%	51.3%	47.9%	45.1%	45.3%	45.6%	47.1%
Pct of Enrollment - Female	49.6%	48.7%	52.1%	54.9%	54.7%	54.4%	52.9%


As results for Partnership retirees become more credible, they will be reported separately.




Emergency Room Visits - State Plan Active Population

January 2023 – December 2023 (Current Period); January 2022 – December 2022 (Prior Period)

ER Visits Per Month



Avoidable ER Visits*



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	30,522	264
Prior	31,931	282


*Avoidable ER visits are those that could have been handled in a non-acute setting (e.g., a doctor's office, clinic, urgent care facility or telehealth)



Emergency Room Visits - State Plan Non-Medicare Retirees


January 2023 – December 2023 (Current Period); January 2022 – December 2022 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	11,831	342
Prior	11,830	331

Avoidable ER Visits*




*Avoidable ER visits are those that could have been handled in a non-acute setting (e.g., a doctor's office, clinic, urgent care facility or telehealth)




Emergency Room Visits - State Plan Medicare Retirees

January 2023 – December 2023 (Current Period); January 2022 – December 2022 (Prior Period)

ER Visits Per Month



Avoidable ER Visits*



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	28,439	478
Prior	32,050	560


*Avoidable ER visits are those that could have been handled in a non-acute setting (e.g., a doctor's office, clinic, urgent care facility or telehealth)



Emergency Room Visits - Partnership Plan (includes retirees)


January 2023 – December 2023 (Current Period); January 2022 – December 2022 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	15,726	253
Prior	15,646	239

Avoidable ER Visits*



*Avoidable ER visits are those that could have been handled in a non-acute setting (e.g., a doctor's office, clinic, urgent care facility or telehealth). As Partnership retiree membership increases, they will be reported separately.



Top 15 Drugs – State Plan Active Population

January 2023 – December 2023 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	OZEMPIC	Diabetes	\$12,699,403	25,422	\$500
2	DUPIXENT	Skin Disorders	\$7,175,624	3,144	\$2,282
3	HUMIRA PEN	Autoimmune Disease	\$6,961,651	2,402	\$2,898
4	STELARA	Psoriasis	\$5,265,871	697	\$7,555
5	SKYRIZI	Psoriasis	\$5,122,177	614	\$8,342
6	TRIKAFTA	Cystic Fibrosis	\$4,078,023	186	\$21,925
7	STRENSIQ	Rare Disorders	\$3,882,036	52	\$74,655
8	VYVANSE	ADHD/Narcolepsy	\$3,239,925	10,396	\$312
9	MOUNJARO	Diabetes	\$2,762,091	4,030	\$685
10	TRULICITY	Diabetes	\$2,003,205	4,071	\$492
11	NURTEC	Migraine	\$1,841,340	2,749	\$670
12	BIKTARVY	Viral Infections/HIV AIDS	\$1,626,768	592	\$2,748
13	VERZENIO	Oncology	\$1,582,147	168	\$9,418
14	MENOPUR	Fertility	\$1,511,129	390	\$3,875
15	XOLAIR	Asthma/COPD	\$1,507,279	866	\$1,741



Top 15 Drugs – State Plan Non-Medicare Retirees

January 2023 – December 2023 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	OZEMPIC	Diabetes	\$4,865,962	9,142	\$532
2	HUMIRA PEN	Autoimmune Disease	\$3,255,834	1,064	\$3,060
3	DUPIXENT	Skin Disorders	\$2,115,098	897	\$2,358
4	SKYRIZI	Psoriasis	\$1,844,989	211	\$8,744
5	STELARA	Psoriasis	\$1,540,292	217	\$7,098
6	MOUNJARO	Diabetes	\$1,473,986	2,022	\$729
7	TRULICITY	Diabetes	\$1,220,946	2,151	\$568
8	TRIKAFTA	Cystic Fibrosis	\$1,004,408	45	\$22,320
9	BIKTARVY	Viral Infections/HIV AIDS	\$964,764	315	\$3,063
10	XOLAIR	Asthma/COPD	\$916,229	458	\$2,001
11	VYVANSE	ADHD/Narcolepsy	\$839,029	2,528	\$332
12	OTEZLA	Autoimmune Disease	\$794,874	412	\$1,929
13	VERZENIO	Oncology	\$757,217	69	\$10,974
14	XARELTO	Blood Disorders	\$746,161	1,563	\$477
15	ELIQUIS	Blood Disorders	\$743,907	1,733	\$429



Top 15 Drugs – State Plan Medicare Retirees

January 2023 – December 2023 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	ELIQUIS	Blood Disorders	\$35,397,432	27,861	\$1,271
2	OZEMPIC	Diabetes	\$22,420,612	13,136	\$1,707
3	JARDIANCE	Diabetes	\$15,829,021	9,902	\$1,599
4	HUMIRA PEN	Autoimmune Disease	\$14,951,727	1,160	\$12,889
5	XARELTO	Blood Disorders	\$12,817,678	9,266	\$1,383
6	REVLIMID	Oncology	\$12,225,956	622	\$19,656
7	VYNDAMAX	Cardiovascular/Heart Disease	\$12,147,951	277	\$43,855
8	TRULICITY	Diabetes	\$11,232,280	6,016	\$1,867
9	JANUVIA	Diabetes	\$9,293,639	6,008	\$1,547
10	DUPIXENT	Skin Disorders	\$9,040,526	1,955	\$4,624
11	FARXIGA	Diabetes	\$8,550,294	5,763	\$1,484
12	STELARA	Psoriasis	\$8,261,807	287	\$28,787
13	TRELEGY ELLIPTA	Asthma/COPD	\$8,040,865	6,882	\$1,168
14	IMBRUVICA	Oncology	\$7,856,728	384	\$20,460
15	MYRBETRIQ	Overactive Bladder/Urinary Incontinence	\$7,614,269	7,068	\$1,077



Top 15 Drugs – Partnership Plan (includes retirees)

January 2023 – December 2023 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	OZEMPIC	Diabetes	\$6,090,471	10,711	\$569
2	HUMIRA PEN	Autoimmune Disease	\$4,662,363	1,361	\$3,426
3	DUPIXENT	Skin Disorders	\$3,862,913	1,559	\$2,478
4	STELARA	Psoriasis	\$3,336,634	356	\$9,373
5	ELIQUIS	Blood Disorders	\$2,511,376	3,252	\$772
6	SKYRIZI	Psoriasis	\$2,057,935	226	\$9,106
7	TRULICITY	Diabetes	\$1,757,820	2,367	\$743
8	VYVANSE	ADHD/Narcolepsy	\$1,611,254	5,478	\$294
9	XTANDI	Oncology	\$1,578,022	103	\$15,321
10	MOUNJARO	Diabetes	\$1,458,635	1,838	\$794
11	JARDIANCE	Diabetes	\$1,419,500	2,983	\$476
12	XARELTO	Blood Disorders	\$1,161,077	1,868	\$622
13	REVLIMID	Oncology	\$1,081,386	76	\$14,229
14	MENOPUR	Fertility	\$1,047,904	255	\$4,109
15	ENBREL SURECLICK	Autoimmune Disease	\$956,842	354	\$2,703

As Partnership retiree membership increases, they will be reported separately.



Top 15 Prescription Drug Disease Indications

State Plan Active Population

January 2023 – December 2023 By Plan Paid

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Diabetes	\$22,895,711	74,107	\$309
2	Autoimmune Disease	\$17,772,775	8,014	\$2,218
3	Oncology	\$15,356,785	5,868	\$2,617
4	Psoriasis	\$14,238,771	3,457	\$4,119
5	Skin Disorders	\$11,797,151	58,631	\$201
6	ADHD/Narcolepsy	\$10,043,554	48,124	\$209
7	Multiple Sclerosis/Neuromuscular Disorders	\$8,861,148	1,451	\$6,107
8	Asthma/COPD	\$7,466,277	67,035	\$111
9	Rare Disorders	\$5,703,972	1,467	\$3,888
10	Viral Infections/HIV AIDS	\$5,438,174	3,077	\$1,767
11	Migraine	\$5,029,724	19,150	\$263
12	Cystic Fibrosis	\$4,591,337	307	\$14,955
13	Vaccines/Immunizing Agents	\$4,586,016	40,588	\$113
14	Mental Health/Neurological Disorders	\$4,498,342	14,654	\$307
15	Depression	\$4,333,304	89,645	\$48



Top 15 Prescription Drug Disease Indications

State Plan Non-Medicare Retirees

January 2023 – December 2023 By Plan Paid

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Diabetes	\$11,843,231	36,345	\$326
2	Autoimmune Disease	\$8,802,967	3,776	\$2,331
3	Oncology	\$8,338,575	3,001	\$2,779
4	Psoriasis	\$4,733,360	1,212	\$3,905
5	Asthma/COPD	\$3,869,795	24,571	\$157
6	Skin Disorders	\$3,647,084	20,690	\$176
7	Multiple Sclerosis/Neuromuscular Disorders	\$3,170,063	676	\$4,689
8	ADHD/Narcolepsy	\$2,672,584	11,442	\$234
9	Lipid/Cholesterol Disorders	\$2,545,662	39,855	\$64
10	Viral Infections/HIV AIDS	\$2,368,250	1,149	\$2,061
11	Blood Disorders	\$2,272,780	5,356	\$424
12	Seizure Disorder	\$2,192,611	16,673	\$132
13	Depression	\$2,180,903	35,453	\$62
14	Vaccines/Immunizing Agents	\$2,126,990	16,687	\$127
15	Cardiovascular/Hypertension	\$2,009,588	67,967	\$30



Top 15 Prescription Drug Disease Indications

State Plan Medicare Retirees

January 2023 – December 2023 By Plan Paid

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Diabetes	\$119,473,009	119,217	\$1,002
2	Oncology	\$96,146,221	14,703	\$6,539
3	Blood Disorders	\$60,177,136	59,448	\$1,012
4	Autoimmune Disease	\$46,411,287	7,408	\$6,265
5	Asthma/COPD	\$38,272,934	83,452	\$459
6	Cardiovascular/Heart Disease	\$28,778,789	23,351	\$1,232
7	Psoriasis	\$26,932,697	2,121	\$12,698
8	Vaccines/Immunizing Agents	\$23,808,421	88,331	\$270
9	Skin Disorders	\$15,659,766	46,582	\$336
10	Lipid/Cholesterol Disorders	\$15,386,125	193,903	\$79
11	Multiple Sclerosis/Neuromuscular Disorders	\$14,587,041	1,355	\$10,765
12	Cardiovascular/Hypertension	\$13,575,797	365,820	\$37
13	Overactive Bladder/Urinary Incontinence	\$12,152,230	19,119	\$636
14	Ophthalmology	\$10,528,344	13,876	\$759
15	Glaucoma	\$9,378,233	34,637	\$271



Top 15 Prescription Drug Disease Indications

Partnership Plan (includes retirees)

January 2023 – December 2023 By Plan Paid

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Diabetes	\$16,293,043	40,712	\$400
2	Oncology	\$16,262,211	4,142	\$3,926
3	Autoimmune Disease	\$11,578,347	4,693	\$2,467
4	Psoriasis	\$7,509,919	1,618	\$4,641
5	Skin Disorders	\$6,018,455	28,911	\$208
6	Asthma/COPD	\$5,180,904	32,936	\$157
7	Blood Disorders	\$4,415,506	8,679	\$509
8	ADHD/Narcolepsy	\$4,230,844	24,179	\$175
9	Vaccines/Immunizing Agents	\$4,229,534	23,325	\$181
10	Multiple Sclerosis/Neuromuscular Disorders	\$3,828,385	763	\$5,018
11	Rare Disorders	\$3,395,067	922	\$3,682
12	Cardiovascular/Heart Disease	\$3,098,270	3,224	\$961
13	Mental Health/Neurological Disorders	\$2,783,640	8,215	\$339
14	Lipid/Cholesterol Disorders	\$2,593,099	42,893	\$60
15	Viral Infections/HIV AIDS	\$2,577,968	1,560	\$1,653

As Partnership retiree membership increases, they will be reported separately.



Top 15 Medical Diagnosis Categories

State Plan Active Population

January 2023 – December 2023 By Plan Paid

Rank	Diagnosis Description	Plan Paid
1	Encounter for screening for malignant neoplasms	\$ 30,374,795.24
2	Encounter for other aftercare and medical care	\$ 28,027,931.27
3	Encounter for general examination without complaint, suspected or reported diagnosis	\$ 23,617,944.30
4	Multiple sclerosis	\$ 15,023,226.12
5	Dorsalgia	\$ 14,218,114.80
6	Other anxiety disorders	\$ 13,533,125.25
7	Major depressive disorder, recurrent	\$ 12,653,714.05
8	Other sepsis	\$ 11,881,695.43
9	Reaction to severe stress, and adjustment disorders	\$ 11,616,685.50
10	Liveborn infants according to place of birth and type of delivery	\$ 11,081,809.96
11	Pervasive developmental disorders	\$ 10,880,011.98
12	Other joint disorder, not elsewhere classified	\$ 9,989,784.10
13	Overweight and obesity	\$ 9,858,136.30
14	Encounter for other special examination without complaint, suspected or reported diagnosis	\$ 9,816,347.03
15	Abdominal and pelvic pain	\$ 9,348,506.23

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories

State Plan Non-Medicare Retirees

January 2023 – December 2023 By Plan Paid

Rank	Diagnosis Description		Plan Paid
1	Encounter for other aftercare and medical care	\$	20,719,799.55
2	Encounter for screening for malignant neoplasms	\$	12,958,347.14
3	Osteoarthritis of knee	\$	6,496,886.45
4	Encounter for general examination without complaint, suspected or reported diagnosis	\$	6,439,534.46
5	Dorsalgia	\$	5,875,665.02
6	Multiple sclerosis	\$	4,999,729.60
7	Osteoarthritis of hip	\$	4,966,468.15
8	Other sepsis	\$	4,945,115.80
9	Alcohol related disorders	\$	4,914,613.87
10	Other spondylopathies	\$	4,553,950.42
11	Other joint disorder, not elsewhere classified	\$	4,450,394.78
12	Atrial fibrillation and flutter	\$	4,249,590.05
13	Major depressive disorder, recurrent	\$	3,936,041.59
14	Sleep disorders	\$	3,752,114.45
15	Malignant neoplasm of breast	\$	3,663,661.89

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories

State Plan Medicare Retirees

January 2023 – December 2023 By Plan Paid

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care	\$ 36,690,096.89
2	Other sepsis	\$ 18,866,057.60
3	Osteoarthritis of knee	\$ 14,673,191.83
4	Type 2 diabetes mellitus	\$ 13,224,082.27
5	Atrial fibrillation and flutter	\$ 12,018,112.25
6	Chronic kidney disease (CKD)	\$ 11,832,141.91
7	Other retinal disorders	\$ 10,762,507.63
8	Dorsalgia	\$ 9,666,788.95
9	Encounter for screening for malignant neoplasms	\$ 9,561,948.66
10	Chronic ischemic heart disease	\$ 9,280,364.37
11	Age-related cataract	\$ 9,207,257.60
12	Other spondylopathies	\$ 7,762,651.46
13	Encounter for general examination without complaint, suspected or reported diagnosis	\$ 7,635,492.06
14	Other joint disorder, not elsewhere classified	\$ 7,634,970.85
15	Osteoarthritis of hip	\$ 7,580,763.16

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories

Partnership Plan (includes retirees)

January 2023 – December 2023 By Plan Paid

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care	\$ 22,313,118.34
2	Encounter for screening for malignant neoplasms	\$ 17,202,945.89
3	Encounter for general examination without complaint, suspected or reported diagnosis	\$ 12,972,327.05
4	Other anxiety disorders	\$ 7,811,088.36
5	Multiple sclerosis	\$ 7,745,503.86
6	Dorsalgia	\$ 7,441,649.70
7	Other sepsis	\$ 7,348,321.39
8	Liveborn infants according to place of birth and type of delivery	\$ 7,217,498.79
9	Other joint disorder, not elsewhere classified	\$ 5,677,536.47
10	Reaction to severe stress, and adjustment disorders	\$ 5,555,777.57
11	Osteoarthritis of knee	\$ 5,439,938.13
12	Major depressive disorder, recurrent	\$ 5,361,126.93
13	Encounter for other special examination without complaint, suspected or reported diagnosis	\$ 5,191,259.32
14	Atrial fibrillation and flutter	\$ 4,632,301.78
15	Abdominal and pelvic pain	\$ 4,543,913.09

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.


²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.

As Partnership retiree membership increases, they will be reported separately.



Distribution of Medical Claims By Membership

January 2023 – December 2023 By Plan Paid– State Plan Active Population




¹ Per Member Per Month



Distribution of Medical Claims By Membership

January 2023 – December 2023 By Plan Paid– State Plan Non-Medicare Population




¹ Per Member Per Month



Distribution of Medical Claims By Membership

January 2023 – December 2023 By Plan Paid– State Plan Medicare Population




¹ Per Member Per Month



Distribution of Medical Claims By Membership

January 2023 – December 2023 By Plan Paid– Partnership Plan (includes retirees)



¹ Per Member Per Month

As Partnership retiree membership increases, they will be reported separately.

